Gain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Recommendation of “Buy” by Brokerages

Gain Therapeutics, Inc. (NASDAQ:GANX) has been assigned an average recommendation of “Buy” from the six brokerages that are presently covering the firm, Marketbeat reports. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $8.20.

Several research firms have issued reports on GANX. Chardan Capital restated a “buy” rating and issued a $6.00 price objective on shares of Gain Therapeutics in a research note on Friday, March 28th. HC Wainwright reissued a “buy” rating and issued a $8.00 target price on shares of Gain Therapeutics in a research report on Thursday, July 3rd.

Hedge Funds Weigh In On Gain Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Kovitz Investment Group Partners LLC purchased a new position in Gain Therapeutics in the first quarter worth $91,000. Dauntless Investment Group LLC purchased a new position in shares of Gain Therapeutics in the 1st quarter valued at about $240,000. Bridgeway Capital Management LLC acquired a new stake in shares of Gain Therapeutics in the fourth quarter valued at about $65,000. Northern Trust Corp boosted its holdings in Gain Therapeutics by 88.2% during the fourth quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock worth $183,000 after buying an additional 39,642 shares in the last quarter. Finally, Marshall Wace LLP acquired a new position in Gain Therapeutics during the fourth quarter worth about $198,000. Institutional investors and hedge funds own 11.97% of the company’s stock.

Gain Therapeutics Stock Performance

Shares of GANX stock opened at $1.86 on Thursday. The company has a market cap of $55.71 million, a P/E ratio of -2.16 and a beta of 0.12. The firm has a fifty day moving average price of $1.83 and a 200 day moving average price of $2.01. The company has a current ratio of 2.22, a quick ratio of 2.22 and a debt-to-equity ratio of 0.05. Gain Therapeutics has a 12 month low of $0.89 and a 12 month high of $3.19.

Gain Therapeutics (NASDAQ:GANX) last posted its earnings results on Wednesday, May 14th. The company reported ($0.16) earnings per share for the quarter, hitting the consensus estimate of ($0.16). Sell-side analysts predict that Gain Therapeutics will post -1 earnings per share for the current fiscal year.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.